Synthesis and antileishmanial activity of lipophilic aromatic aminoalcohols

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 1067-1072

  Corrales, Roberta Novaes Reis ^a   Pinheiro, Liliane Sena ^a   Coimbra, Elaine Soares ^a   Da Silva, Adilson David ^a   Le Hyaric, Mireille ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Aminoalcohols; Antileishmanial activity; Leishmania; Polyamines

Indexed keywords

AMINOALCOHOL; AMPHOTERICIN B; AROMATIC AMINE; ETHYLENEDIAMINE DERIVATIVE; N DECYL AMINOALCOHOL; N DODECANOYL ETHYLENEDIAMINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; POLYAMINE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; LEISHMANIA; LEISHMANIA CHAGASI; LEISHMANIA MAJOR; LIPOPHILICITY; NONHUMAN; PROMASTIGOTE; ANIMAL; DRUG EFFECT; LIPID METABOLISM; METABOLISM; REVIEW; SYNTHESIS;

LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR;

AMINO ALCOHOLS; ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA; LIPID METABOLISM; POLYAMINES;

EID: 77955908215     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.106     Document Type: Article

References (26)

1. WHO (2005) Tropical Disease Research. Progress 2003-2004. Special Program for Research and Training in Tropical Diseases. World Health Organization, Geneva.
2. Bern, C., Maguire, J.H., and Alvar, J. (2008) Complexities of assessing the disease burden attributable to Leishmaniasis. PLoS Negl. Trop. Dis. 2, 1-8.
3. Jeronimo, S.M.B., de Queiroz Sousa, A., and Pearson, R.D. (2006) Leishmaniasis. In Tropical Infectious Diseases: Principles, Pathogens and Practice. Guerrant, R.L., Walker, D.H., and Weller, P.F., Eds. Churchill Livingstone Elsevier, Edinburgh. pp. 1095-1113.
4. Alvar, J., Yactayo, S., and Bern, C. (2006) Leishmaniasis and poverty. Trends Parasitol. 22, 552-557.
5. Cruz, A.K., De Toledo, J.S., Falade, M., Terrão, M.C., Kamchonwongpaisan, S., Kyle, D.E., and Uthaipibull, C. (2009) Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review. Curr. Drug Targets 10, 178-192.
6. Frézard, F., Demicheli, C., and Ribeiro R.R. (2009) Pentavalent antimonials: new perspectives for old drugs. Molecules 14, 2317-2336
7. Del Olmo, E.M., Alves, M., Lopéz, J.L., Inchaustti, A., Yaluff, G., and De Arias, A.R. (2002) Leishmanicidal activity of some aliphatic diamines and amino-alcohols. Bioorg. Med. Chem. Lett. 12, 659-662.
8. Reis, R.C.N., Coimbra, E.S., Almeida, C.G., Júnior, W.V., De Almeida, A.C.F., Forezi, L.S.M., Almeida, M.V., and Le Hyaric, M. (2008) Antileishmanial activity of aldonamides and N-acyl-diamine derivatives. TheScientificWorldJOURNAL 8, 752-756.
9. Costa, C.F., Coimbra, E.S., Braga, F.G., Reis, R.C.N., Silva, A.D., and De Almeida, M.V. (2009) Preparation and antileishmanial activity of lipophilic N-alkyl diamines. Biomed. Pharmacother. 63, 40-42.
10. Labadie, G.R., Choi, S.R., and Avery, M.A. (2004) Diamine derivatives with antiparasitic activities. Bioorg. Med. Chem. Lett. 14, 615-619.
11. Rebollo, O., del Olmo, E., Ruiz, G., López-Pérez, J.L., Giménez, A., and San Feliciano, A. (2008) Leishmanicidal and trypanocidal activities of 2-aminocyclohexanol and 1,2- cyclohexanediamine derivatives. Bioorg. Med. Chem. Lett. 18, 184-187.
12. Taylor, M.C., Kaur, H., Blessington, B., Kelly, J.M., and Wilkinson, S.R. (2008) Validation of spermidine synthase as a drug target in African trypanosomes. Biochem. J. 15, 563-569.
13. Heby, O., Persson, L., and Rentala, M. (2007) Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas disease, and leishmaniases. Amino Acids 33, 359-366.
14. Baiocco, P., Franceshini, S., Ilari, A., and Colotti, G. (2009) Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis. Protein Pept. Lett. 16, 196-200.
15. Castro-Pinto, D.B., Genestra, M., Menezes, G.B., Wagahabi, M., Gonçalves, A., De Nigris Del Cistia, C., Sant'Anna, C.M., Leon, L.L., and Mendonça-Lima, L. (2008) Cloning and expression of trypanothione reductase from a New World Leishmania species. Arch. Microbiol. 189, 375-384.
16. Basselin, M. and Robert-Gero, M. (1998) Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol. Res. 84, 78-83.
17. Long, D., Church, T.J., Jacobsen, J.R., Jiang, L., Saito, DR., and Stergiades, I. (2007) Preparation of 8-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as opioid receptor antagonists PCT. Int. Appl. WO 2007103187 A2 20070913.
18. Aranapakam, V., Davis, J.M., Grosu, G.T., Baker, J., Ellingboe, J., Zask, A., Levin, J.I., Sandanayaka, V.P., Du, M., Skotnicki, J.S., DiJoseph, J.F., Sung, A., Sharr, M.A., Killar, L.M., Walter, T., Jin, G., Cowling, R., Tillett, J., Zhao, W., McDevitt, J., and Xu, Z. (2003) Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 46, 2376-2396. (Pubitemid 36637922)
19. Eckstein, M., Zajaczkowska, J., Krupinska, J., and Michna, M. (1986) Derivatives of 2-N-arylalkylamino-2-methyl-1-propanol with antiarrhythmic activity. Pol. J. Pharmacol. Pharm. 38, 215-220.
20. Mauleon, D., Pujol, M., and Rosell, G. (1988) β-Adrenergic antagonists: N-alkyl and N-amidoethyl(arylalkoxy)propanolamines related to propranolol. Eur. J. Med. Chem. 23, 421-426.
21. Almeida, C.G., Darbois, G.D., Amaral, L.M., Diniz, C.G., and Le Hyaric, M. (2010) Relationship between structure and antibacterial activity of lipophilic N-acyldiamines. Biomed. Pharmacother. 64, 287-290.
22. 13C NMR: 5a (139.1; 129.0-128.5; 126.6; 73.7; 72.4; 69.3; 61.2; 52.0; 36.4); 5b (138.9; 129.0-128.5; 126.4; 73.6; 72.4; 68.9; 63.1; 52.2; 49.0; 36.2; 30.9); 5c (138.9; 129.0-127.5; 126.4; 73.7; 72.4; 69.9; 68.6; 53.6; 44.4; 36.3; 23.1); 5d (138.9; 129.0-128.5; 126.4; 73.2; 72.5; 67.9; 59.5; 58.4; 57.5; 36.3); 7a (173.9; 138.9; 129.0-128.5; 126.4; 73.5; 72.4; 68.7; 51.8; 48.9; 38.8; 36.9; 36.3; 31.8-22.7; 14.2); 7b (174.1; 138.9; 129.0-128.5; 126.5; 73.4; 72.5; 68.4; 51.8; 38.5; 36.9; 36.3; 32.0-22.8; 14.2); 7c (174.1; 13.8; 129.0-128.5; 126.4; 76.7; 72.5; 68.3; 51.8; 48.9; 38.5; 36.8; 36.3; 32.0-22.8; 14.2); 9a (139.0; 129.0-128.5; 126.5; 73.7; 72.5; 68.8; 52.1; 50.0; 36.4; 31.9-22.8; 14.2); 9b (139.0; 129.0-128.5; 126.4; 73.3; 72.4; 69.5; 58.1; 55.8; 36.4; 32.0-22.8; 14.2).
23. Braga, F.G., Coimbra, E.S., Matos, M.O., Carmo, A.M.L., Cancio, M.D., and Da Silva, A.D. (2007) Synthesis and biological evaluation of some 6-substituted purines. Eur. J. Med. Chem. 42, 530-537.
24. Escobar, P., Sangeeta, M., Marques, C., and Croft, S.L. (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop. 81, 151-157.
25. Croft, S.L., Seifert, K., and Yardley, V. (2006) Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123, 399-410.
26. Croft, S.L., Barrett, M.P., and Urbina, J.A. (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21, 508-512.